Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Immunogenicity, and Effectiveness of Gardasil in Adolescents
NCT00092547Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2003
- Primary completion
- Nov 2005
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started Oct 2003; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00092547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092547.